<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03630159</url>
  </required_header>
  <id_info>
    <org_study_id>CCTL019J2101</org_study_id>
    <secondary_id>2018-000973-57</secondary_id>
    <nct_id>NCT03630159</nct_id>
  </id_info>
  <brief_title>Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients</brief_title>
  <acronym>PORTIA</acronym>
  <official_title>Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, open-label, phase Ib study to evaluate the safety and efficacy of the
      administration of tisagenlecleucel in combination with pembrolizumab in patients with r/r
      DLBCL who have received 2 or more lines of systemic therapy, including an anti-CD20 and
      anthracycline based chemotherapy and having failed to or are not candidates for ASCT. The
      study will consist of 2 parts: dose timing selection part and expansion part.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2018</start_date>
  <completion_date type="Anticipated">July 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 18, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>None (Open label)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of participants recieving pembrolizumab per protocol schedule</measure>
    <time_frame>21 days after first pembrolizumab infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Timing part: Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>21 days after first pembrolizumab infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Expansion part: Overall response rate (ORR)</measure>
    <time_frame>3 month post tisagenlecleucel infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In vivo cellular kinetics of tisagenlecleucel in blood, bone marrow, lymph nodes and other tissues by qPCR and flow cytometry</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of pembrolizumab dosing strategy on the cellular kinetics of tisagenlecleucel by qPCR and flow cytometry</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity measured by antibody titres specific to tisagenlecleucel molecule and by the presence of T lymphocytes activated by the tisagenlecleucel protein</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Tisagenlecleucel+Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tisagenlecleucel</intervention_name>
    <description>Gene modified autologous T cells</description>
    <arm_group_label>Tisagenlecleucel+Pembrolizumab</arm_group_label>
    <other_name>CTL019</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>anti PD-1</description>
    <arm_group_label>Tisagenlecleucel+Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed DLBCL per local histopathology assessment.

          -  Relapsed or refractory disease after having recieved 2 or more lines of systemic
             therapy, including anti-CD20 and anthracycline based chemotherapy, and either having
             progressed after (or relapsed after) ASCT, or being not candidates for or not
             consenting to ASCT.

          -  Measurable disease at time of enrollment

          -  ECOG performance status that is either 0 or 1 at screening.

        Exclusion Criteria:

          -  Patients with Richter's transformation, and Burkitt lymphoma, and primary DLBCL of
             CNS.

          -  Prior treatment with any prior anti-CD19/anti-CD3 therapy, or any other anti-CD19
             therapy.

          -  Patients with active CNS involvement are excluded, except if the CNS involvement has
             been effectively treated and provided that local treatment was &gt;4 weeks before
             enrollment.

          -  Prior allogeneic HSCT.

          -  Unstable angina and/or myocardial infarction and/or coronary artery bypass graft
             (CABG), or stroke within 6 months prior to screening, and/or impaired cardiac function
             or clinically significant cardiac disease

          -  Patients with a history of prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2,
             anti-CTLA-4 antibodies, other immune checkpoint inhibitors.

          -  History of interstitial lung disease or (non-infectious) pneumonitis that required
             oral or intravenous steroids (other than COPD exacerbation) or current pneumonitis.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Emory University School of Medicine SC CTL019</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachael Maynard Morffi</last_name>
      <phone>+1 404 778 3708</phone>
      <email>rachael.morffi@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Edmund K. Waller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center Hematology and Oncology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Hoekstra</last_name>
      <phone>773-834-8980</phone>
      <email>ehoekstra1@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Riedell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital and Medical Center U of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nichola Fell</last_name>
      <phone>913-588-6029</phone>
      <email>nfell@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph P McGuirk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Perelman School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya Latorre</last_name>
      <phone>215-746-8902</phone>
      <email>Tanya.Latorre@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Jakub Svoboda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 1, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma tisagenlecleucel</keyword>
  <keyword>Diffuse Large B-cell Lymphoma</keyword>
  <keyword>CTL019</keyword>
  <keyword>PORTIA</keyword>
  <keyword>DLBCL</keyword>
  <keyword>tisagenlecleucel</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>r/r Diffuse large B-cell Lymphoma</keyword>
  <keyword>relapsed/refractory Diffuse large B-cell Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

